Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
KFKevin FitzgeraldMFMaria Frank-KamenetskySSSvetlana Shulga‐MorskayaALAbigail LiebowBRBrian R. Bettencourt
Alnylam Pharmaceuticals (United States) · The University of Texas Southwestern Medical Center · +3 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
572
total citations
- FWCI
- 60.03
- Percentile
- 100%
- References
- 42
Citations per year
Authors
20Topics & keywords
Topics
Keywords
- PCSK9
- Tolerability
- Placebo
- Kexin
- Clinical endpoint
- Proprotein convertase
- Pharmacodynamics
- Medicine
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.